"Therapeutic Equivalency" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The relative equivalency in the efficacy of different modes of treatment of a disease, most often used to compare the efficacy of different pharmaceuticals to treat a given disease.
| Descriptor ID |
D013810
|
| MeSH Number(s) |
G03.787.559 G07.690.725.898
|
| Concept/Terms |
Therapeutic Equivalency- Therapeutic Equivalency
- Clinical Equivalencies
- Equivalencies, Clinical
- Equivalency, Clinical
- Generic Equivalency
- Equivalencies, Generic
- Equivalency, Generic
- Generic Equivalencies
- Equivalencies, Therapeutic
- Therapeutic Equivalencies
- Equivalency, Therapeutic
- Bioequivalence
- Bioequivalences
- Clinical Equivalency
|
Below are MeSH descriptors whose meaning is more general than "Therapeutic Equivalency".
Below are MeSH descriptors whose meaning is more specific than "Therapeutic Equivalency".
This graph shows the total number of publications written about "Therapeutic Equivalency" by people in this website by year, and whether "Therapeutic Equivalency" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 2 | 2 |
| 1996 | 1 | 0 | 1 |
| 2000 | 0 | 3 | 3 |
| 2001 | 0 | 2 | 2 |
| 2006 | 0 | 2 | 2 |
| 2007 | 1 | 2 | 3 |
| 2009 | 1 | 2 | 3 |
| 2010 | 1 | 1 | 2 |
| 2015 | 0 | 1 | 1 |
| 2024 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Therapeutic Equivalency" by people in Profiles.
-
Javidnia M, Irier HA, Kassim S, Cho SJ. Remote Regulatory Assessments of Bioavailability/Bioequivalence Study Conduct by the Office of Study Integrity and Surveillance. AAPS PharmSciTech. 2024 Oct 10; 25(7):240.
-
Zheng R, Lam E, Altshuler P, Crutcher M, Lavu H, Yeo CJ, Stickle D, Leiby B, Kraft WK. Pharmacokinetics of apixaban in patients undergoing pancreaticoduodenectomy (PAP-UP). Int J Clin Pharmacol Ther. 2024 Jul; 62(7):319-325.
-
Falchook G, Patnaik A, Richardson DL, Harvey RD, Sharma MR, Hafez N, Hamilton E, Piha-Paul SA, Barve M, Wise-Draper T, Patel MR, Dowlati A, Pascuzzo J, Tang SC, Faltermeier C, Malinowska IA, Shtessel L, Striha A, Potocka E. A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors. Clin Ther. 2024 03; 46(3):228-238.
-
Choudhry NK, Denberg TD, Qaseem A. Improving Adherence to Therapy and Clinical Outcomes While Containing Costs: Opportunities From the Greater Use of Generic Medications: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med. 2016 Jan 05; 164(1):41-9.
-
Blackstone EA, Fuhr JP. Biosimilars and innovation: an analysis of the possibility of increased competition in biopharmaceuticals. Future Med Chem. 2010 Nov; 2(11):1641-9.
-
Colon-Gonzalez F, Kraft WK. Pharmacokinetic evaluation of fosaprepitant dimeglumine. Expert Opin Drug Metab Toxicol. 2010 Oct; 6(10):1277-86.
-
Fuhr JP. Biosimilars and follow-on biologics. Expert Rev Pharmacoecon Outcomes Res. 2009 Apr; 9(2):149-50.
-
Cushing DJ, Adams MP, Cooper WD, Kowey PR, Lipicky RJ. Bioequivalence of 2 intravenous amiodarone formulations in healthy participants. J Clin Pharmacol. 2009 Apr; 49(4):407-15.
-
Varki R, Pequignot E, Leavitt MC, Ferber A, Kraft WK. A glycosylated recombinant human granulocyte colony stimulating factor produced in a novel protein production system (AVI-014) in healthy subjects: a first-in human, single dose, controlled study. BMC Clin Pharmacol. 2009; 9:2.
-
Ermer JC, Shojaei A, Pennick M, Anderson CS, Silverberg A, Youcha SH. Bioavailability of triple-bead mixed amphetamine salts compared with a dose-augmentation strategy of mixed amphetamine salts extended release plus mixed amphetamine salts immediate release. Curr Med Res Opin. 2007 May; 23(5):1067-75.